
|Articles|October 6, 2015
Rayner's Recently Acquired Ophteis OVD Range and What This Means for Cataract Surgery
Professor Steve Arshinoff and Rayner CEO Tim Clover announce Rayner's recent acquisition of the Ophteis OVD range at the Company's celebratory event, held at the 2015 ESCRS in Barcelona.
Advertisement
Redirect to video article
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA guidance to help accelerate cell and gene therapies
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
The Residency Report: Cardiovascular risk scores as a window into ocular disease
4
Outlook Therapeutics resubmits BLA for bevacizumab-vikg (ONS-5010/LYTENAVA)
5





















